Cell Source, Inc.
Cell Source, Inc. (CLCS): 7 pipeline candidates · ~0 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.0 months
D/E -1.01 · 0% dilution
Lead: Phase 1
7 candidates
N/A
N/A
A transparent, data-derived signal for Cell Source, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$56.4M
Cash
$1K
Quarterly Burn
$600K
Runway
0.0 mo
Revenue
—
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| Anti-Rejection Anti-Viral Veto Cell | Preclinical |
| Anti-Viral Veto Cell | Phase 1 |
| CAR-T and Veto Cell combination (CAR-T Veto Cell therapy) | Preclinical |
| Megadose Drug Combination | Phase 1 |
| VETO CAR-T | Preclinical |
| Veto Cell | Phase 1 |
| Veto Cell technology | Preclinical |
Frequently asked questions
How many drug candidates are in Cell Source, Inc.'s pipeline?
Cell Source, Inc. (CLCS) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cell Source, Inc.'s lead drug candidate?
Cell Source, Inc.'s most advanced tracked candidate is Anti-Rejection Anti-Viral Veto Cell (Preclinical) for Prevent rejection and potentially reduce viral infections in patients undergoing allogeneic HSCT (support of stem cell transplantations).
What is Cell Source, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cell Source, Inc. has approximately 0.0 months of cash runway.
What is Cell Source, Inc.'s market capitalization?
Cell Source, Inc.'s market capitalization is approximately $56.4M.
Who is the CEO of Cell Source, Inc.?
Mr. Itamar Shimrat is the chief executive officer of Cell Source, Inc. (CLCS).
Get the full picture on Cell Source, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.